METTL3 facilitates renal cell carcinoma progression by PLOD2 m
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
17 Jan 2024
17 Jan 2024
Historique:
received:
02
09
2023
accepted:
21
12
2023
revised:
14
12
2023
medline:
18
1
2024
pubmed:
18
1
2024
entrez:
17
1
2024
Statut:
epublish
Résumé
N6-methyladenosine (m
Identifiants
pubmed: 38233403
doi: 10.1038/s41419-023-06411-w
pii: 10.1038/s41419-023-06411-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Subventions
Organisme : Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation)
ID : BK20211064
Organisme : Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation)
ID : BK20200180
Informations de copyright
© 2024. The Author(s).
Références
Jian Y, Yang K, Sun X, Zhao J, Huang K, Aldanakh A, et al. Current advance of immune evasion mechanisms and emerging immunotherapies in renal cell carcinoma. Front Immunol. 2021;12:639636.
pubmed: 33767709
pmcid: 7985340
doi: 10.3389/fimmu.2021.639636
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6.
pubmed: 22575960
doi: 10.1038/nature11112
Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m(6)A RNA methylation. Nat Rev Genet. 2014;15:293–306.
pubmed: 24662220
doi: 10.1038/nrg3724
Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28:507–17.
pubmed: 29686311
pmcid: 5951805
doi: 10.1038/s41422-018-0034-6
Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, et al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18:112.
pubmed: 31230592
pmcid: 6589893
doi: 10.1186/s12943-019-1038-7
Xu QC, Tien YC, Shi YH, Chen S, Zhu YQ, Huang XT, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner. Oncogene. 2022;41:1622–33.
pubmed: 35094011
pmcid: 8913368
doi: 10.1038/s41388-022-02185-1
Wang W, Shao F, Yang X, Wang J, Zhu R, Yang Y, et al. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N(6)-methyladenosine-dependent YTHDF binding. Nat Commun. 2021;12:3803.
pubmed: 34155197
pmcid: 8217513
doi: 10.1038/s41467-021-23501-5
Chen Y, Zhou C, Sun Y, He X, Xue D. m6A RNA modification modulates gene expression and cancer-related pathways in clear cell renal cell carcinoma. Epigenomics. 2020;12:87–99.
pubmed: 31856595
doi: 10.2217/epi-2019-0182
Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007;9:1221–35.
pubmed: 17536958
doi: 10.1089/ars.2007.1628
Xu Q, Kong N, Zhao Y, Wu Q, Wang X, Xun X, et al. Pan-cancer analyses reveal oncogenic and immunological role of PLOD2. Front Genet. 2022;13:864655.
pubmed: 35586565
pmcid: 9108334
doi: 10.3389/fgene.2022.864655
Du H, Pang M, Hou X, Yuan S, Sun L. PLOD2 in cancer research. Biomed Pharmacother. 2017;90:670–6.
pubmed: 28415047
doi: 10.1016/j.biopha.2017.04.023
Qi Y, Xu R. Roles of PLODs in collagen synthesis and cancer progression. Front Cell Dev Biol. 2018;6:66.
pubmed: 30003082
pmcid: 6031748
doi: 10.3389/fcell.2018.00066
Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, et al. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 2013;3:1190–205.
pubmed: 23906982
doi: 10.1158/2159-8290.CD-13-0118
Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011;11:80.
pubmed: 21338529
pmcid: 3050856
doi: 10.1186/1471-2407-11-80
Cao C, Ma Q, Huang X, Li A, Liu J, Ye J, et al. Targeted demethylation of the PLOD2 mRNA inhibits the proliferation and migration of renal cell carcinoma. Front Mol Biosci. 2021;8:675683.
pubmed: 34179084
pmcid: 8220145
doi: 10.3389/fmolb.2021.675683
Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63:306–17.
pubmed: 27373337
pmcid: 4958592
doi: 10.1016/j.molcel.2016.05.041
Du Y, Hou G, Zhang H, Dou J, He J, Guo Y, et al. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Res. 2018;46:5195–208.
pubmed: 29506078
pmcid: 6007514
doi: 10.1093/nar/gky156
Scholler E, Weichmann F, Treiber T, Ringle S, Treiber N, Flatley A, et al. Interactions, localization, and phosphorylation of the m(6)A generating METTL3-METTL14-WTAP complex. RNA. 2018;24:499–512.
pubmed: 29348140
pmcid: 5855951
doi: 10.1261/rna.064063.117
Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593:597–601.
pubmed: 33902106
pmcid: 7613134
doi: 10.1038/s41586-021-03536-w
Zuurmond AM, van der Slot-Verhoeven AJ, van Dura EA, De Groot J, Bank RA. Minoxidil exerts different inhibitory effects on gene expression of lysyl hydroxylase 1, 2, and 3: implications for collagen cross-linking and treatment of fibrosis. Matrix Biol. 2005;24:261–70.
pubmed: 15908192
doi: 10.1016/j.matbio.2005.04.002
Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285–95.
pubmed: 29476152
pmcid: 5826585
doi: 10.1038/s41556-018-0045-z
Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117–20.
pubmed: 24284625
doi: 10.1038/nature12730
Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28:616–24.
pubmed: 29789545
pmcid: 5993786
doi: 10.1038/s41422-018-0040-8
Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol Cancer. 2019;18:103.
pubmed: 31142332
pmcid: 6540575
doi: 10.1186/s12943-019-1033-z
Song Y, Zheng S, Wang J, Long H, Fang L, Wang G, et al. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget. 2017;8:41947–62.
pubmed: 28410212
pmcid: 5522040
doi: 10.18632/oncotarget.16710
Du H, Chen Y, Hou X, Huang Y, Wei X, Yu X, et al. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC. Cell Death Dis. 2017;8:e3143.
pubmed: 29072684
pmcid: 5680920
doi: 10.1038/cddis.2017.553
Xu F, Zhang J, Hu G, Liu L, Liang W. Hypoxia and TGF-beta1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. Cancer Cell Int. 2017;17:54.
pubmed: 28507454
pmcid: 5427545
doi: 10.1186/s12935-017-0420-z
Blanco MA, LeRoy G, Khan Z, Aleckovic M, Zee BM, Garcia BA, et al. Global secretome analysis identifies novel mediators of bone metastasis. Cell Res. 2012;22:1339–55.
pubmed: 22688892
pmcid: 3434351
doi: 10.1038/cr.2012.89
Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6:11.
pubmed: 18442412
pmcid: 2386807
doi: 10.1186/1741-7015-6-11
Su H, Yang F, Fu R, Trinh B, Sun N, Liu J, et al. Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. Nature. 2022;610:366–72.
pubmed: 36198801
pmcid: 9588640
doi: 10.1038/s41586-022-05169-z
Taketo K, Konno M, Asai A, Koseki J, Toratani M, Satoh T, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52:621–9.
pubmed: 29345285
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappaB/MYC signaling network. Oncogene. 2019;38:3667–80.
pubmed: 30659266
doi: 10.1038/s41388-019-0683-z
Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67:2254–70.
pubmed: 29171881
doi: 10.1002/hep.29683
Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369–76.
pubmed: 28920958
pmcid: 5677536
doi: 10.1038/nm.4416
Wang J, Zhang C, He W, Gou X. Effect of m(6)A RNA methylation regulators on malignant progression and prognosis in renal clear cell carcinoma. Front Oncol. 2020;10:3.
pubmed: 32038982
pmcid: 6992564
doi: 10.3389/fonc.2020.00003
Zhang QJ, Luan JC, Song LB, Cong R, Ji CJ, Zhou X, et al. m6A RNA methylation regulators correlate with malignant progression and have potential predictive values in clear cell renal cell carcinoma. Exp Cell Res. 2020;392:112015.
pubmed: 32333907
doi: 10.1016/j.yexcr.2020.112015
Sormendi S, Wielockx B. Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment. Front Immunol. 2018;9:40.
pubmed: 29434587
pmcid: 5796897
doi: 10.3389/fimmu.2018.00040
Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997;94:8104–9.
pubmed: 9223322
pmcid: 21564
doi: 10.1073/pnas.94.15.8104
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485–90.
pubmed: 9697772
doi: 10.1038/28867
Yang N, Wang T, Li Q, Han F, Wang Z, Zhu R, et al. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1alpha. J Cell Physiol. 2021;236:3863–80.
pubmed: 33305825
doi: 10.1002/jcp.30128
Yang Y, Cheng C, He B, Du X, Liu J, Xia H, et al. Cigarette smoking, by accelerating the cell cycle, promotes the progression of non-small cell lung cancer through an HIF-1alpha-METTL3-m(6)A/CDK2AP2 axis. J Hazard Mater. 2023;455:131556.
pubmed: 37156046
doi: 10.1016/j.jhazmat.2023.131556
Wang C, Kadigamuwa C, Wu S, Gao Y, Chen W, Gu Y, et al. RNA N6-methyladenosine (m6A) methyltransferase-like 3 facilitates tumorigenesis and cisplatin resistance of arecoline-exposed oral carcinoma. Cells. 2022;11:3605.